Iron After a Hair-Loss Assessment: What an Alternate-Day Trial Found

If a hair-loss assessment during GLP-1 treatment leads to an iron prescription, ask about both the dose and the schedule. Bring the prescription and your test results to the follow-up appointment so the discussion starts with your own treatment.

The schedules delivered equal totals over different periods

A Swiss randomized trial enrolled 150 women aged 18 to 45 with ferritin ≤30 micrograms/L and hemoglobin >11 g/dL. [1]

• Consecutive group: 100 mg iron daily for 90 days, then 90 days of placebo.
• Alternate group: 100 mg iron alternating with placebo for 180 days.

At equal totals, median ferritin was 43.8 versus 44.8 micrograms/L (P = 0.98). The consecutive group had more digestive side effects on iron-taking days: longitudinal prevalence ratio 1.56 (95% CI 1.38–1.77). [1]

Read the calendar beside the ferritin result

The comparison spans three versus six months. It establishes neither faster replenishment nor hair regrowth with alternate-day dosing. [1]

That distinction changes the consultation question. Rather than asking which schedule is “best for hair,” ask which schedule suits the reason you need iron, how quickly correction is needed and what you can tolerate. A study can inform that discussion without supplying your prescription.

Ferritin and hemoglobin answer different questions

NIH describes ferritin as a measure of iron stores and notes that it can decline before iron-deficiency anemia develops. Inflammation can raise ferritin. Hemoglobin and ferritin therefore need clinical interpretation rather than comparison with a single number from a hair forum. [2]

Keep a copy of your results with the collection date, units and laboratory reference ranges. Ask the clinician to write the diagnosis beside them. “Iron deficiency,” “iron-deficiency anemia” and “hair shedding under assessment” describe different parts of the problem; make sure you know which applies to you.

Report symptoms before abandoning the prescription

High supplemental iron doses can cause nausea, constipation, abdominal discomfort and other digestive effects. The US adult upper limit is 45 mg daily for healthy people, but clinicians may prescribe higher doses for treatment. The trial's 100 mg dose is a research regimen, not an over-the-counter starting recommendation. [2]

If treatment is difficult to tolerate, record the product, dose, time taken, meals and symptoms. Tell the prescriber how many planned doses you managed to take. A note saying “constipation after the third dose; skipped the next two” gives a clearer account than “iron did not agree with me.” Ask what change, if any, is appropriate and when to report back.

NIH also identifies interactions with medicines including levothyroxine and levodopa. Have a pharmacist check your full medication and supplement list before setting a timetable. [2]

Agree on the next blood test and hair review

Ask for a written plan specifying the product, elemental iron dose, dosing days, administration instructions and review date. Keep the blood-test follow-up and the hair assessment as separate entries. An improved laboratory result does not document a change in hair density.

For the hair review, take photographs with the same part, lighting and camera distance. Bring the dates of shedding onset, weight changes and treatment changes. Ask what the clinician will assess if shedding persists after the iron problem is addressed, rather than continuing supplements indefinitely on the assumption that every remaining hair concern needs more iron.

This study does not supply a GLP-1-specific prescription. For the broader assessment, read the hair-shedding preparation guide. If you are also considering zinc, review zinc dose and testing questions.

Printed book

How to Keep Your Face on GLP-1

$12.95 + free shipping

Order Now

✓ 30 day money back guarantee

This article provides general education, not a diagnosis or an individual treatment plan. Medication information refers to US sources. Discuss medication, nutrition and cosmetic treatment decisions with qualified clinicians.